RAPT Therapeutics announced the appointment of Michael Listgarten as General Counsel. Listgarten has over 25 years of law firm and in-house experience, focused on helping biopharmaceutical companies manage the transition from late-stage clinical development to commercial entities. Most recently, he served as Vice President of Healthcare Law & Chief Compliance Officer at Adamas Pharmaceuticals, overseeing legal support for the commercial and medical functions, advising on critical transactions, and ensuring compliance with the complex system of laws and regulations governing the biopharmaceutical industry.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RAPT:
- RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Rapt Therapeutics to participate in a conference call with JPMorgan
- Capital One remains bullish on RPT193 as Rapt initiates Phase 2a Asthma study
- Rapt Therapeutics announces initiation of Phase 2a trial of RPT193
- Cantor biopharma/biotech analysts hold analyst/industry conference call